Descrição

The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 bilhão durante 2021-2027, crescendo a uma taxa composta de crescimento anual (CAGR) de 17.1% durante o período de previsão, de acordo com a empresa de dados e análise StrategyHelix.

O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2017-2020 e previsão para 2027 covering key market aspects like sales value for non-small cell lung cancer (NSCLC) drug. The China non-small cell lung cancer (NSCLC) drug market is segmented on the basis of type, incidence of gene mutation. Por tipo, it is categorized into adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, e outros. By incidence of gene mutation, the non-small cell lung cancer (NSCLC) drug market is divided into ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), e outros.

The report has profiled some of the key players of the market such as AstraZeneca plc., Betta Pharmaceuticals Co. Ltda., Bristol-Myers Squibb Company, Merck KGaA, Novartis International AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Co. Ltda.

O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.

Escopo do relatório

Tipo: adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, e outros
Incidence of gene mutation: ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), e outros
Anos considerados: este relatório cobre o período 2017 para 2027

Principais benefícios para as partes interessadas

Get a comprehensive picture of the China non-small cell lung cancer (NSCLC) drug market
Identifique setores de crescimento e tendências para investimento
Understand what the future of the non-small cell lung cancer (NSCLC) drug market in China looks like
Identifique o cenário competitivo e a janela de oportunidade

Índice

1. Definição de mercado
2. Metodologia de Pesquisa
3. Dados de mercado & Panorama
3.1 Valor de mercado
3.2 Previsão de valor de mercado
4. Non-Small Cell Lung Cancer (NSCLC) Drug Market by Type
4.1 Adenocarcinoma
4.2 Large Cell Carcinoma
4.3 Sarcomatoid Carcinoma
4.4 Squamous-Cell Carcinoma
4.5 Outros
5. Non-Small Cell Lung Cancer (NSCLC) Drug Market by Incidence Of Gene Mutation
5.1 Alk (Anaplastic Lymphoma Kinase)
5.2 Egfr (Epidermal Growth Factor Receptor)
5.3 Kras (Kirsten Rat Sarcoma Viral Oncogene Homologue)
5.4 Outros
6. Perfis de empresa
6.1 AstraZeneca plc.
6.2 Betta Pharmaceuticals Co., Ltda.
6.3 Bristol-Myers Squibb Company
6.4 Merck KGaA
6.5 Novartis International AG
6.6 Pfizer, Inc..
6.7 Roche Holding AG
6.8 Takeda Pharmaceutical Co. Ltda.
7. Apêndice
7.1 Sobre StrategyHelix
7.2 Isenção de responsabilidade